Stock up big on intelligent remote robots for intensive care

⚕️Telehealth hot spot                                                                                                                                                                                                                                                                                                                                                                                                                 August 02, 2024 | [Read Online]( *sponsored by Good day, 360! Here are our top investing ideas today. And don’t forget to join us in [Market Masters]( - the hottest trading room around 🔥. Be the best prepared trader on the Street! FOCUS LIST🔎 VSEE - Up over 190% in the pre-market after announcing it has partnered with Ava Robotics to develop a VSee-powered Ava robot that allows providers to extend their reach and provide personalized care remotely XCUR - Up over 50% in pre after receiving positive listing determination from Nasdaq ADAP - Up over 6% in pre after receiving U.S. FDA accelerated approval of TECELRA® (afamitresgene autoleucel), the first approved engineered cell therapy for a solid tumor *sponsored by Masterworks​ This painting sold for 8 million and everyday investors profited When the painting by master Claude Monet (you may have heard of him) was bought for $6.8 million and sold for a cool $8 million just 631 days later, investors in shares of the offering received their share of the net proceeds. All thanks to Masterworks, the award-winning platform for investing in blue-chip art. To date, every one of Masterworks’ 16 sales out of its portfolio has returned a profit to investors. With 3 recent sales, investors realized net annualized returns of 17.6%, 21.5% and 35%. How does it work? Simple, Masterworks files each offering with the SEC so that nearly anyone can invest in highly coveted artworks for just a fraction of the price of the entire piece. Shares of every offering are limited, but 360 readers can skip the waitlist with this exclusive link. [Skip the Waitlist](. *Past performance is not indicative of future returns, investing involves risk. See disclosures masterworks.com/cd HOTLIST🔥 VSEE - Up over 190% in the pre-market after announcing it has partnered with Ava Robotics to develop a VSee-powered Ava robot that allows providers to extend their reach and provide personalized care remotely VSee Health, Inc. (VSEE) is a provider of comprehensive telehealth services that customize workflow streams and enhance patient care. In the after-hours yesterday, the [company announced]( that it had partnered with Ava Robotics, a developer of intelligent robots for the workplace, to develop telepresence solutions for the inpatient intensive care market, including the development of a VSee-powered Ava robot that allows providers to extend their reach and provide personalized care remotely. With the first commercial product launched in June, the Ava Robot is expected to be able to improve tele-stroke operations, and additional uses will be identified in the medical field as use of the Robot expands. VSEE stock traded up over 190% in the pre-market in reaction to the news. The first target for bulls is the after-hours high at $7.54. Above it, targets to the upside are $8, $10 and $12. Below $7.54, targets to the downside are $6.30, $6, $5.60, $5, $4 and then a gap fill at $2.43. XCUR - Up over 50% in pre after receiving positive listing determination from Nasdaq Exicure, Inc. (XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. In the after-hours yesterday, the [company announced]( that on July 31, 2024, the company received formal notice that the Nasdaq Hearings Panel has determined to continue the company’s listing subject to the company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by September 16, 2024. The Company is diligently working to timely satisfy the terms of the Panel’s decision and to ensure the Company’s continued listing on Nasdaq. The stock traded up over 50% in the pre-market in reaction to the news. The first target for bulls is the prior resistance level at $0.76. Beyond that, targets to the upside are $0.80, and then the after-hours high at $0.8955. Above that, $0.95, $1, $1.10, $1.20 and $1.50 come into play. Below $0.76, targets to the downside are $0.70, $0.65, $0.55 and then a gap fill at $0.4949. ADAP - Up over 6% in pre after receiving U.S. FDA accelerated approval of TECELRA® (afamitresgene autoleucel), the first approved engineered cell therapy for a solid tumor Adaptimmune Therapeutics plc (ADAP) is a clinical-stage biopharmaceutical company that provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. In the pre-market this morning, the [company announced]( that the U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. The stock traded up over 6% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $1.54. Above it, targets to the upside are $1.65, $1.80 and $2.05. Below $1.54, targets to the downside are $1.40, $1.30 and then $1.25. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](